Resolax2 mg

Resolax is indicated for the treatment of the following condition:

Established / Approved Indication

• Chronic Idiopathic Constipation (CIC) in adults — Resolax is approved for adults whose chronic constipation has not been adequately controlled with conventional laxatives, or in whom laxatives fail to provide adequate relief.

Other Uses (Evidence-Based, Not Primary FDA Label Use)

• Some clinical studies and specialist guidelines support use of Resolax for constipation associated with opioid use or for constipation-predominant symptoms in certain neurogenic bowel conditions, generally as a second-line option after standard laxatives; this use should only be undertaken on physician advice.

Resolax is not indicated for children/adolescents under 18 years, as safety and efficacy have not been established in this age group.

Each film-coated tablet contains Prucalopride Succinate equivalent to 1 mg or 2 mg of prucalopride (base), along with pharmaceutically approved excipients.

Prucalopride Succinate is typically available as oral tablets in 1 mg and 2 mg strengths.

Resolax is the succinate salt of prucalopride, a selective, high-affinity agonist at serotonin 5-HT4 receptors. It belongs to a class of medicines called gastrointestinal prokinetic agents, which work by directly stimulating gut motility rather than by drawing water into the bowel (osmotic laxatives) or irritating the bowel wall (stimulant laxatives).

Resolax is used for the long-term management of chronic idiopathic constipation in adults who have not responded adequately to conventional laxatives. Unlike some earlier 5-HT4 agonists, Resolax is highly selective for the 5-HT4 receptor, which is the basis for its favorable cardiovascular safety profile at approved doses.

Resolax belongs to the therapeutic class of Selective Serotonin (5-HT4) Receptor Agonists, used as a gastroprokinetic agent for chronic constipation.

Prucalopride Succinate is a selective, high-affinity serotonin 5-HT4 receptor agonist. Stimulation of 5-HT4 receptors located on enteric neurons in the gut wall triggers the release of acetylcholine and other neurotransmitters, which increases high-amplitude propagating contractions (HAPCs) in the colon. This accelerates colonic transit and increases the frequency of bowel movements.

Pharmacokinetics

• Absorption: Rapidly absorbed after oral administration; peak plasma concentration reached within 2–3 hours; absolute bioavailability ≥90%. Food does not significantly affect absorption.
• Distribution: Low plasma protein binding (approximately 30%); large volume of distribution.
• Metabolism: Undergoes limited hepatic metabolism; most of the dose is excreted unchanged.
• Elimination: Mainly excreted unchanged in urine (approximately 60–65%) and to a lesser extent in feces. Elimination half-life is approximately 24 hours, supporting once-daily dosing.

Resolax tablets should be swallowed whole with a glass of water. It may be taken with or without food, but it is best to take it at the same time each day for consistent effect. Do not crush, chew, or split the tablet unless advised by a physician.

Resolax has a low potential for drug interactions, as it is only a minor substrate of CYP3A4 and has low potential to inhibit or induce major drug-metabolizing enzymes. Clinically relevant interactions include:

• Strong CYP3A4/P-glycoprotein inhibitors (e.g., ketoconazole): May increase Resolax plasma exposure; use with caution, particularly in patients with renal impairment.
• Erythromycin: Co-administration with Resolax has been associated with increased erythromycin plasma levels; clinical significance is not fully established, but caution is advised.

No clinically significant interactions have been demonstrated with warfarin, digoxin, oral contraceptives, or paroxetine. Always inform the physician of all medicines being taken before starting Resolax.

The most commonly reported side effects of Resolax, especially during the first days of treatment, include:

• Headache
• Nausea
• Diarrhea
• Abdominal pain and abdominal distension
• Dizziness
• Vomiting
• Flatulence
• Fatigue

These effects are usually transient, occur mainly on the first day of treatment, and typically resolve within a few days with continued use. Less commonly, hypersensitivity reactions (rash, urticaria, swelling of the face, difficulty breathing) have been reported and require immediate discontinuation and medical attention (see Precautions and Warnings). Postmarketing reports have also noted mood or behavioral changes such as new or worsening anxiety, depression, or suicidal thoughts in some patients; any such symptom should be reported to a physician promptly.

Pregnancy: Data on the use of Resolax in pregnant women are limited. Animal reproduction studies have not shown adverse fetal effects at high multiples of the human dose, but this does not confirm safety in humans. Resolax should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: Resolax passes into breast milk. A decision should be made, in consultation with a physician, whether to discontinue breastfeeding or discontinue the medicine, taking into account the benefit of breastfeeding for the infant and the clinical need of the mother.

The following precautions apply to the use of Resolax:

• Renal impairment: Dose reduction is required in severe renal impairment; use is not recommended in patients with end-stage renal disease requiring dialysis, as pharmacokinetics have not been established (see Use in Special Populations).
• Hepatic impairment: Use with caution in patients with severe hepatic impairment.
• Mood and behavioral changes: Patients and caregivers should be alert to new or worsening depression, anxiety, agitation, or suicidal thoughts, particularly within the first weeks of treatment; discontinue Resolax and seek medical advice immediately if these occur.
• Severe diarrhea: If severe diarrhea occurs, it may reduce the effectiveness of oral contraceptives; an additional contraceptive method is advised during and for a period after the episode.
• Fluid/electrolyte loss: Significant diarrhea can lead to dehydration or electrolyte imbalance; monitor and manage appropriately, especially in elderly or frail patients.
• Not recommended for use in patients under 18 years of age (see Pediatric Uses).

Overdose of Resolax may cause an exaggeration of its known pharmacodynamic effects, such as headache, nausea, and diarrhea. There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact emergency services/poison control. Management is supportive and symptomatic; fluid and electrolyte status should be monitored and corrected as needed, particularly if significant diarrhea has occurred.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Renal Impairment

No dose adjustment is generally needed in mild to moderate renal impairment. In severe renal impairment (creatinine clearance <30 mL/min), the recommended dose of Resolax is 1 mg once daily. Use in patients on dialysis is not recommended as data are insufficient.

Hepatic Impairment

No dose adjustment is generally needed in mild to moderate hepatic impairment. Resolax should be used with caution in severe hepatic impairment.

Elderly (>65 years)

A starting dose of 1 mg once daily is recommended in elderly patients, as they may have reduced renal function leading to higher drug exposure; the dose may be increased to 2 mg once daily if tolerated and clinically indicated.

Pediatric Population

Safety and efficacy of Resolax have not been established in patients under 18 years of age; use in this population is not recommended (see Pediatric Uses).

Resolax may be used for long-term management of chronic idiopathic constipation under medical supervision. If there is no improvement in symptoms after 4 weeks of appropriate dosing, treatment should be reassessed by the prescribing physician, and continued use should be based on ongoing clinical benefit. Do not use for longer than advised without periodic medical review.

Prucalopride Succinate belongs to the drug class of Gastrointestinal Prokinetic Agents, specifically Selective Serotonin 5-HT4 Receptor Agonists.

Prucalopride Succinate acts as a selective agonist at serotonin 5-HT4 receptors located on enteric neurons within the wall of the gastrointestinal tract. By stimulating these receptors, Prucalopride Succinate promotes the release of acetylcholine and other excitatory neurotransmitters from enteric neurons, which enhances high-amplitude propagating contractions (HAPCs) — the primary motor pattern responsible for mass movement of colonic contents. This accelerates gastric emptying, small bowel, and colonic transit, resulting in increased frequency and ease of bowel movements. Because Prucalopride Succinate is highly selective for the 5-HT4 receptor with minimal affinity for other serotonin receptor subtypes (including hERG cardiac channels), it does not carry the cardiovascular risk (e.g., valvulopathy, arrhythmia) that led to the withdrawal of some older, less-selective 5-HT4 agonists.

The safety and efficacy of Resolax have not been established in pediatric patients under 18 years of age. A clinical trial in patients aged 6 months to 17 years with functional constipation did not demonstrate efficacy over placebo. Therefore, Resolax is not recommended for use in children or adolescents outside of a physician-directed clinical context, and only established adult dosing should guide use in adults.